Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
NCT06144086Phase 2Completed
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of foscenvivint in Liver cirrhosis (LC). Started May 2024; status: completed.
02
Drugs
foscenvivint
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06144086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144086.